Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report Journal Article

Local Library Link: Find It @ Loyola

Authors: Micallef, I. N.; Stiff, P. J.; Nademanee, A. P.; Maziarz, R. T.; Horwitz, M. E.; Stadtmauer, E. A.; Kaufman, J. L.; McCarty, J. M.; Vargo, R.; Cheverton, P. D.; Struijs, M.; Bolwell, B.; DiPersio, J. F.
Article Title: Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report
Abstract: The purpose of this report is to analyze long-term clinical outcomes of patients exposed to plerixafor plus granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization. This was a study of patients with non-Hodgkin lymphoma (NHL; n = 167) and multiple myeloma (MM; n = 163) who were enrolled in the long-term follow-up of 2 pivotal phase III studies (NCT00741325 and NCT00741780) of 240 microg/kg plerixafor plus 10 microg/kg G-CSF, or placebo plus 10 microg/kg G-CSF to mobilize and collect CD34(+) cells for autologous hematopoietic stem cell transplantation. Overall survival (OS) and progression-free survival (PFS) were evaluated over a 5-year period following the first dose of plerixafor or placebo. The probability of OS was not significantly different in patients with NHL or MM treated with plerixafor or placebo (NHL: 64%; 95% confidence interval [CI], 56% to 71% versus 56%; 95% CI, 44% to 67%, respectively; MM: 64%; 95% CI, 54% to 72% versus 64%; 95% CI, 53% to 73%, respectively). In addition, there was no statistically significant difference in the probability of PFS over 5 years between treatment groups in patients with NHL (50%; 95% CI, 44% to 67% for plerixafor versus 43%; 95% CI, 31% to 54% for placebo) or those with MM (17%; 95% CI, 10% to 24% for plerixafor versus 30%; 95% CI, 21% to 40% for placebo). In this long-term follow-up study, the addition of plerixafor to G-CSF for stem cell mobilization did not affect 5-year survival in patients with NHL or patients with MM.
Journal Title: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536; 1083-8791
Publisher: Elsevier Inc  
Journal Place: United States
Date Published: 2018
Language: eng
DOI/URL:

S1083-8791(18)30056-9
Notes: LR: 20180425; CI: Copyright (c) 2018; GR: P30 CA016520/CA/NCI NIH HHS/United States; JID: 9600628; OTO: NOTNLM; 2017/06/21 00:00 [received]; 2018/01/26 00:00 [accepted]; 2018/02/08 06:00 [pubmed]; 2018/02/08 06:00 [medline]; 2018/02/08 06:00 [entrez]; aheadofprint